ＭａｂＧｅｎｅｓｉｓ is engaged in the research and development of antibody drugs for dogs and cats and had 19 pipeline programs as of August. 4 of these are said to have already been out-licensed. The current share price was ¥588 as of 15:30, a sharp decline of ¥124 from the previous day.
ＭａｂＧｅｎｅｓｉｓ conducts research and development of antibody drugs for dogs and cats. The article reports that the company had 19 pipeline programs as of the time of reporting.
It also notes that 4 of the company's programs have been out-licensed under arrangements involving the provision of technology.
The article also reports the company's share price, stating that the current price was ¥588 as of 15:30, down ¥124 from the previous day, or 17.42%.